Aggregation of insulin into insoluble fibrils (fibrillation) may lead to complications for diabetes patients such as reduced insulin potency, occlusion of insulin delivery devices, or potentially increased immunological potential. Even after extensive investigation of fibril formation in regular human insulin, there are little published data about the intrinsic fibrillation of fast-acting analogs. This article investigates and compares the intrinsic fibrillation of three fast-acting insulin analogs—lispro, aspart, and glulisine—as a function of their primary protein structure and exclusive of the stabilizing excipients that are added to their respective commercial formulations.
Methods:
The insulin analogs underwent a buffer exchange into phosphate-buffered saline to remove formulation excipients and then were heated and agitated to characterize intrinsic fibrillation potentials devoid of excipient stabilizing effects. Different analytical methods were used to determine the amount of intrinsic fibrillation for the analogs. After initial lag times, intrinsic fibrillation was detected by an amyloid-specific stain. Precipitation of insulin was confirmed by ultraviolet analysis of soluble insulin and gravimetric measurement of insoluble insulin. Electron microscopy showed dense fibrous material, with individual fibrils that are shorter than typical insulin fibrils. Higher resolution kinetic analyses were carried out in 96-well plates to provide more accurate measures of lag times and fibril growth rates.
Results:
All three analogs exhibited longer lag times and slower intrinsic fibrillation rates than human insulin, with glulisine and lispro rates slower than aspart. This is the first study comparing the intrinsic fibrillation of fast-acting insulin analogs without the stabilizing excipients found in their commercial formulations.
Conclusions:
Data show different intrinsic fibrillation potentials based on primary molecular structures when the formulation excipients that are critical for stability are absent. Understanding intrinsic fibrillation potential is critical for evaluating insulin analog stability and device compatibility.
MahlerHCFriessWGrauschopfUKieseS. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci.2009; 98 (9): 2909–34.
2.
ManningMCChouDKMurphyBMPayneRWKatayamaDS. Stability of protein pharmaceuticals: An update. Pharm Res.2010; 27 (4): 544–75.
3.
WeissWF4thYoungTMRobertsCJ. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci.2009; 98 (4): 1246–77.
4.
PatelJKothariRTungaRRitterNMTungaBS. Stability considerations for biopharmaceuticals, part 1. BioProc Int.2011; 9: 20–31.
5.
Morozova-RocheLMalisauskasM. A false paradise — Mixed blessings in the protein universe: The amyloid as a new challenge in drug development. Curr Med Chem.2007; 14 (11): 1221–30.
6.
WangW. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm.2005; 289 (1–2): 1–30.
7.
MaasCHermelingSBoumaBJiskootWGebbinkMF. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem.2007; 282 (4): 2229–36.
8.
RosenbergAS. Effects of protein aggregates: An immunologic perspective. AAPS J.2006; 8 (3): E501–7.
9.
ChitiFWebsterPTaddeiNClarkAStefaniMRamponiGDobsonCM. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA.1999; 96 (7): 3590–4.
10.
TaylorJPHardyJFischbeckKH. Toxic proteins in neurodegenerative disease. Science.2002; 296 (5575): 1991–5.
11.
RossCAPoirierMA. Protein aggregation and neurodegenerative disease. Nat Med.2004; 10 Suppl: S10–7.
NelsonRSawayaMRBalbirnieMMadsenAØRiekelCGrotheREisenbergD. Structure of the cross-beta spine of amyloid-like fibrils. Nature.2005; 435 (7043): 773–8.
14.
PetkovaATIshiiYBalbachJJAntzutkinONLeapmanRDDelaglioFTyckoR. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA.2002; 99 (26): 16742–7.
15.
TyckoR. Progress towards a molecular-level structural understanding of amyloid fibrils. Curr Opin Struct Biol.2004; 14 (1): 96–103.
NielsenLKhuranaRCoatsAFrokjaerSBrangeJVyasSUverskyVNFinkAL. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry.2001; 40 (20): 6036–46.
18.
SluzkyVTamadaJAKlibanovAMLangerR. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci USA.1991; 88 (21): 9377–81.
19.
SluzkyVKlibanovAMLangerR. Mechanism of insulin aggregation and stabilization in agitated aqueous solutions. Biotechnol Bioeng.1992; 40 (8): 895–903.
JimenezJLNettletonEJBouchardMRobinsonCVDobsonCMSaibilHR. The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci USA.2002; 99 (14): 9196–201.
22.
MannoMCraparoEFPodestàABuloneDCarrottaRMartoranaVTianaGSan BiagioPL. Kinetics of different processes in human insulin amyloid formation. J Mol Biol.2007; 366 (1): 258–74.
23.
AhmadAUverskyVNHongDFinkAL. Early events in the fibrillation of monomeric insulin. J Biol Chem.2005; 280 (52): 42669–75.
GroenningMFrokjaerSVestergaardB. Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process. Curr Protein Pept Sci.2009; 10 (5): 509–28.
PryceR. Diabetic ketoacidosis caused by exposure of insulin pump to heat and sunlight. BMJ.2009; 338: a2218.
28.
Rahuel-ClermontSFrenchCAKaarsholmNCDunnMFChouCI. Mechanisms of stabilization of the insulin hexamer through allosteric ligand interactions. Biochemistry.1997; 36 (19): 5837–45.
29.
WhittinghamJLEdwardsDJAntsonAAClarksonJMDodsonGG. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro –> Asp insulin analogues. Biochemistry.1998; 37 (33): 11516–23.
30.
DerewendaUDerewendaZDodsonEJDodsonGGReynoldsCDSmithGDSparksCSwensonD. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature.1989; 338 (6216): 594–6.
31.
BakaysaDLRadziukJHavelHABraderMLLiSDoddSWBealsJMPekarAHBremsDN. Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: Dissociation of a protein-ligand complex. Protein Sci.1996; 5 (12): 2521–31.
32.
CiszakEBealsJMFrankBHBakerJCCarterNDSmithGD. Role of C-terminal B-chain residues in insulin assembly: The structure of hexameric LysB28ProB29-human insulin. Structure.1995; 3 (6): 615–22.
33.
RichardsJPStickelmeyerMPFloraDBChanceREFrankBHDeFelippisMR. Self-association properties of monomeric insulin analogs under formulation conditions. Pharm Res.1998; 15 (9): 1434–41.
34.
RaskinPGuthrieRALeiterLRiisAJovanovicL. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care.2000; 23 (5): 583–8.
35.
BrangeJVølundA. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev.1999; 35 (2–3): 307–35.
36.
HirschIB. Insulin analogues. N Engl J Med.2005; 352 (2): 174–83.
37.
BeckerRH. Insulin glulisine complementing basal insulins: A review of structure and activity. Diabetes Technol Ther.2007; 9 (1): 109–21.
38.
HollemanFHoekstraJB. Insulin lispro. N Engl J Med.1997; 337 (3): 176–83.
39.
KerwinBA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. J Pharm Sci.2008; 97 (8): 2924–35.
40.
HarrisonDMGarrattCJ. The accurate measurement of insulin molarity. Biochem J.1969; 113 (4): 733–4.
41.
KrügerPGilgeGCabukYWollmerA. Cooperativity and intermediate states in the T—-R-structural transformation of insulin. Biol Chem Hoppe Seyler.1990; 371 (8): 669–73.
42.
TeskaBAlarconJPettisRJRandolphTCarpenterJ. Effect of phenol and m-cresol depletion on analog insulin conformational stability. AAPS J.2011; 12: S1. http://www.aapsi.org/abstracts/NBC_2011/T2077.pdf. Accessed January 12, 2012.
43.
KodaliRWetzelR. Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol.2007; 17 (1): 48–57.
44.
LeVineH3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods in Enzymol.1999; 309: 274–84.
45.
GroenningMNorrmanMFlinkJMvan de WeertMBukrinskyJTSchluckebierGFrokjaerS. Binding mode of Thioflavin T in insulin amyloid fibrils. J Struct Biol.2007; 159 (3): 483–97.
46.
MeinhardtJSachseCHortschanskyPGrigorieffNFändrichM. Abeta(1–40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J Mol Biol.2009; 386 (3): 869–77.
47.
NelsonRSawayaMRBalbirnieMMadsenAØRiekelCGrotheREisenbergD. Structure of the cross-beta spine of amyloid-like fibrils. Nature.2005; 435 (7043): 773–8.
48.
PedersenJSDikovDFlinkJLHjulerHAChristiansenGOtzenDE. The changing face of glucagon fibrillation: Structural polymorphism and conformational imprinting. J Mol Biol.2006; 355 (3): 501–23.
49.
HortschanskyPSchroeckhVChristopeitTZandomeneghiGFändrichM. The aggregation kinetics of Alzheimer's beta-amyloid peptide is controlled by stochastic nucleation. Protein Sci.2005; 14 (7): 1753–9.
50.
XueWFHomansSWRadfordSE. Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc Natl Acad Sci USA.2008; 105 (26): 8926–31.
51.
UverskyVNLiJFinkAL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem.2001; 276 (14): 10737–44.
52.
KusumotoYLomakinATeplowDBBenedekGB. Temperature dependence of amyloid beta-protein fibrillization. Proc Natl Acad Sci USA.1998; 95 (21): 12277–82.
53.
ChitiFStefaniMTaddeiNRamponiGDobsonCM. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature.2003; 424 (6950): 805–8.
54.
HammarströmPJiangXHurshmanARPowersETKellyJW. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci USA.2002; 99Suppl 4: 16427–32.
55.
de la PazM LópezSerranoL. Sequence determinants of amyloid fibril formation. Proc Natl Acad Sci.2004; 101 (1): 87–92.
56.
AndersenCBOtzenDChristiansenGRischelC. Glucagon amyloid-like fibril morphology is selected via morphology-dependent growth inhibition. Biochemistry.2007; 46 (24): 7314–24.
57.
BouchardMZurdoJNettletonEJDobsonCMRobinsonCV. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci.2000; 9 (10): 1960–7.
58.
ParavastuAKLeapmanRDYauWMTyckoR. Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci USA.2008; 105 (47): 18349–54.
MannoMCraparoEFMartoranaVBuloneDSan BiagioPL. Kinetics of insulin aggregation: Disentanglement of amyloid fibrillation from large-size cluster formation. Biophys J.2006; 90 (12): 4585–91.
61.
ZhengJLiuCSawayaMRVadlaBKhanSWoodsRJEisenbergDGouxWJNowickJS. Macrocyclic β-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide. J Am Chem Soc.2011; 133 (9): 3144–57.
62.
GiehmLOtzenDE. Strategies to increase the reproducibility of protein fibrillization in plate reader assays. Anal Biochem.2010; 400 (2): 270–81.
63.
EvansKCBergerEPChoCGWeisgraberKHLansburyPTJr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA.1995; 92 (3): 763–7.
64.
KimYSRandolphTWStevensFJCarpenterJF. Kinetics and energetics of assembly, nucleation, and growth of aggregates and fibrils for an amyloidogenic protein. Insights into transition states from pressure, temperature, and co-solute studies. J Biol Chem.2002; 277 (30): 27240–6.
65.
AndersenCBOtzenDChristiansenGRischelC. Glucagon amyloid-like fibril morphology is selected via morphology-dependent growth inhibition. Biochemistry.2007; 46 (24): 7314–24.
66.
BrangeJ. The new era of biotech insulin analogues. Diabetologia.1997; 40Suppl 2: S48–53.
67.
FändrichM, 2007. Absolute correlation between lag time and growth rate in the spontaneous formation of several amyloid-like aggregates and fibrils. J Mol Biol.2007; 365 (5): 1266–70.
68.
GroenningMFrokjaerSVestergaardB. Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process. Curr Protein Pept Sci.2009; 10 (5): 509–28.
69.
LudwigDBWebbJNFernandezCCarpenterJFRandolphTW. Quaternary conformational stability: The effect of reversible self-association on the fibrillation of two insulin analogs. Biotechnol Bioeng.2011. Epub ahead of print.
